Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8,942
datasets available to search
ShareScore release 0.9.0
Dataset results
8,942 results for “Prostate”
Transcriptomic analysis of KDM4B-mediated gene in C4-2B prostate cancer cells
GEO Series GSE147481. Homo sapiens. 2 samples. Type: Expression profiling by array.
Intronic Circular RNA hsa_circ_0092339 Plays as Molecular Sponge in Castration-resistance Prostate Cancer by hsa-mir-940/C-MYC Axis
GEO Series GSE185910. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Treatment of prostate cancer cell lines DU-145 and LNCaP with zebularine
GEO Series GSE51629. Homo sapiens. 12 samples. Type: Expression profiling by array.
High-throughput profiling of human castration-resistant prostate cancer cell lines
GEO Series GSE154576. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Changes in gene expression caused by loss of Med1 in the mouse prostate
GEO Series GSE69124. Mus musculus. 12 samples. Type: Expression profiling by array.
Prostate Adenocarcinoma: Candidate Genomic Signatures Prognostic of Biochemical Failure
GEO Series GSE7949. Homo sapiens. 21 samples. Type: Genome variation profiling by genome tiling array.
Tamoxifen-induced Ghr deletion in WT mouse prostates
GEO Series GSE197640. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
Aberrant super-enhancer landscape in enzalutamide-resistant prostate cancer cells
GEO Series GSE228308. Homo sapiens. 2 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Dataset related to article "Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity."
<p>OBJECTIVE:</p> <p>Prostate cancer represents the second most common malignancy in the world and majority of patients have diagnosis of localized disease. The aim of the present study was to compare two cohorts of patients treated with moderate hypofractionation (MHRT) or stereotactic body radiation therapy (SBRT).</p> <p>METHODS:</p> <p>We included patients treated between 2010 and 2015. Inclusion criteria were: adenocarcinoma of the prostate; class risks low or intermediate; WHO performance status 0-2. We evaluated rectal, gastrointestinal toxicity and genitourinary. Measures of outcome were biochemical disease-free survival and overall survival. Propensity score was used to approximate the balance in covariates.</p> <p>RESULTS:</p> <p>209 patients were included, treated with MHRT (<em>n</em> = 109) or SBRT (<em>n</em> = 100). Median follow-up time was 37.4 months. Rates of biochemical disease-free survival at 1- and 3 years were 100 and 95%, respectively. There was no significant difference between the two groups (<em>p</em> = 0.868). Rates of overall survival at 1- and 3 years were 100 and 97.1%, respectively with no differences between the two groups (<em>p</em> = 0.312). After propensity scoring matching, no differences were observed in terms of acute and late rectal and gastrointestinal toxicity. While mild genitourinary side-effects were more common in SBRT group (45.5% <em>vs</em> 19.5 %), Grade 2 and 3 toxicity was increased after MHRT (11.7% <em>vs</em> 2.6 %; <em>p</em> = 0.029).</p> <p>CONCLUSIONS:</p> <p>Moderate hypofractionation and SBRT are two effective and safe options for the treatment of low- and intermediate-risk prostate cancer. The analysis showed no difference in terms of disease's control and survival but increased moderate and severe toxicity after MHRT.</p> <p>ADVANCES IN KNOWLEDGE:</p> <p>Moderate hypofractionation and SBRT are comparable in terms of efficacy while moderate and severe toxicity is more common in the first one.</p>
Dataset related to article "Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy."
<p>PURPOSE:</p> <p>This study explores the efficacy and safety of reirradiation with modern radiation therapy techniques in patients previously irradiated for prostate cancer and affected by local relapse of disease.</p> <p>METHODS AND MATERIALS:</p> <p>Patients affected by previously irradiated prostate cancer were enrolled in this reirradiation study if they had a biochemical relapse and a <sup>11</sup>C-choline positron emission tomography scan revealing the presence of a local recurrence of disease. Reirradiation consisted of a stereotactic treatment delivered by image guided radiation therapy-volumetric modulated arc therapy with flattening filter-free technology in 5 daily fractions.</p> <p>RESULTS:</p> <p>Twenty-three patients underwent reirradiation to the prostate, prostatic bed, or prostate and local recurrence. Re-treatment consisted of a median total dose of 25 Gy in 5 fractions. A biochemical response was observed in all cases. Acute toxicity was mainly genitourinary (GU) grade 1 to 2 (n = 13; 56.5%). One patient (4.3%) had grade 3 hematuria. A grade 1 GU late toxicity was registered in 4 patients (17.4%) and grade 3 in 1 patient (4.3%, urethral obstruction). Gastrointestinal toxicity was negligible. Regression analysis showed that only a short elapsed time in months from primary radiation therapy was significantly correlated with acute GU toxicity. After a median follow-up of 33 months (range, 5-58 months), the median biochemical recurrence-free survival was 19 months, and the 2-year biochemical recurrence-free survival (BRFS) was 41.7%. Median local control was 30 months; the 2-year local control rate was 58.1%.</p> <p>CONCLUSIONS:</p> <p>Reirradiation of patients with prostate cancer who underwent previous radiation therapy is a valuable option that can be safely considered to delay the beginning of hormonal treatment.</p>
Dataset related to article "p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study."
<p>BACKGROUND:</p> <p>There is an unmet clinical need for more biochemical specific tests that may detect clinically significant recurrent PCa at an early stage after radical prostatectomy (RP). Our purpose is to test the hypothesis that p2PSA (Index test) detects prostate cancer relapse (BCR) earlier than the current Reference Standard Test (total prostate-specific antigen [tPSA]) in patients who underwent RP for localized PCa.</p> <p>METHODS:</p> <p>This is an observational, prospective, cohort, follow-up study in patients subjected to RALP (robotic assisted laparoscopic radical prostatectomy) for clinically localized PCa from January 2013 to July 2013 at a high-volume Institution (450 average RP/year). A blood sample, for tPSA and p2PSA, was prospectively drawn after 3, 6, and 12 months and then every 6 months during the following two years. The primary outcome is to determine whether or not kinetics in rising of p2PSA significantly anticipates the tPSA kinetics. Exploratory data analysis was used to identify relationship between different variables.</p> <p>RESULTS:</p> <p>Over 134 patients 20 BCRs were detected according to tPSA cut-off. Five patients showed a contemporary increase of tPSA and p2PSA, 11 presented a p2PSA increase earlier than tPSA increase (13.9 months ±9.7). In four patients, the increase of PSA was not associated with a p2PSA>0.8 pg/mL. The correlation between tPSA and p2PSA according to Sperman's rho coefficient was statistically significant at 3, 6, 18 and 30 months: 0.416 (P<0.01), 0.255 (P<0.01), 0.359 (P<0.01) and 0.413 (P<0.01) respectively. When subjects were stratified according to stage/grade and margins (positive vs. negative), patients with higher stage and positive surgical margins could be considered the target categories. The low rate of observed BCR and high rate of p2PSA false positive are the main limitations.</p> <p>CONCLUSIONS:</p> <p>The current findings showed that p2PSA might be more sensitive than tPSA in detecting earlier BCR within 3-year follow-up. Further studies with a longer follow-up and larger population remain mandatory before considering p2PSA for clinical decision-making.</p>
A Cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for Benign Prostatic Hyperplasia in Nigeria: a middle income perspective; Using an Interactive Markov Model
<p>Background: The number of Nigerian men presenting with benign prostatic hyperplasia is on the rise because of increase awareness about the ailment. With the renewed effort by the national health insurance scheme to cover the informal sector, it becomes imperative to determine the cost implication for managing Benign Prostatic Hyperplasia (BPH) and the cost effective drug combination to be adopted. The objective of this study is to estimate cost effective analysis (CEA) of fixed -dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy from the health service provider perspective design. Methods: An interactive Markov’s model was used to generate incremental cost per QALY and incremental cost per life years gained. 2.9 million Men who were 50 years of age were fed into the model. The outcome measures included: costs of drug treatment, consultation, acute urinary retention(AUR), transurethral resection of prostate(TURP), hospitalisation post TURP, and quality adjusted life years (QALYs), incremental cost per life years gained, and incremental cost per QALY gained Results: fixed-dose combination of dutasteride and tamsulosin (FDCT) produced an Incremental cost-effectiveness ratios of US$1481.92 per Quality adjusted for life-years saved Conclusion: Universal FDCT provision for Nigeria has major economic implications. This study in the context of its limitations has demonstrated the cost effectiveness of FDCT for the long term treatment of patients with moderate to severe BPH from the perspective of a developing country. Currently, there are few studies available to give economic data evidence to policy makers in Nigeria which is applicable to developing countries with similar economies. As such, the findings in this study will be relevant to policy makers in these countries</p>
DCE-MRI prostate images
<p>A 3mm slice fat-suppressed T2W fast spin-echo sequence (TR/TE/ETL: 3400 ms/85 ms/13) is used to acquire images in sagittal and oblique coronal planes, the latter planes being orientated perpendicular or parallel to the prostate PZ – rectal wall axis. Three-dimensional T2W fast spin-echo (TR/TE/ETL: 3600 ms}/143 ms/109, slice thickness: 1.25 mm) images are then acquired in an oblique axial plane.The nominal matrix and FoV of the 3D T2W fast spin-echo images are 320x256 and 280x240 mm<sup>2</sup>, respectively, thereby affording sub-millimetric pixel resolution within the imaging plane.<br> DCE-MRI is performed using a fat suppressed 3D T$_1$ VIBE sequence (TR/TE/Flip angle: 3.25 ms/1.12 ms/10 degrees; Matrix: 256x192; FoV: 280x210 (with 75% rectangular FoV); slab of 16 partitions of 3.5 mm thickness; temporal resolution: 6 s/slab over approximately 5 min). A power injector (Medrad, Indianola, USA) is used to provide a bolus injection of Gd-DTPA (Dotarem, Guerbet, Roissy, France) at a dose of 0.2 ml Gd-DTPA/kg of body weight.</p>
Dataset related to article "Evaluation of Semen Self-Sampling Yield Predictors and CTC Isolation by Multi-Color Flow Cytometry for Liquid Biopsy of Localized Prostate Cancer"
<p><strong>Abstract</strong></p><p>Liquid biopsy (LB) for prostate cancer (PCa) detection could represent an alternative to biopsy. Seminal fluid (SF) is a source of PCa-specific biomarkers, as 40% of ejaculate derives from the prostate. We tested the feasibility of an SF-based LB by evaluating the yield of semen self-sampling in a cohort of >750 patients with clinically localized PCa. The overall SF collection yield was 18.2% (39% when considering only compliant patients), with about a half of the patients (53.15%) not consenting to SF donation. Independent favorable predictors for SF collection were younger age and lower prostate volume. We implemented a protocol to enrich prostate-derived cells by multi-color flow cytometry and applied it on SF and urine samples from 100 patients. The number of prostate-enriched cells (SYTO-16+ PSMA+ CD45-) was variable, with higher numbers of cells isolated from SF than urine (<i>p</i> value < 0.001). Putative cancer cells (EpCAMhigh) were 2% of isolated cells in both specimens. The fraction of EpCAMhigh cells over prostate-enriched cells (PSMA+) significantly correlated with patient age in both semen and urine, but not with other clinical parameters, such as Gleason Score, ISUP, or TNM stage. Hence, enumeration of prostate-derived cells is not sufficient to guide PCa diagnosis; additional molecular analyses to detect patient-specific cancer lesions will be needed</p>
Dataset related to article "Role of 11 C-choline PET/CT in radiation therapy planning of patients with prostate cancer"
<p>This record contains raw data related to article "Role of 11 C-choline PET/CT in radiation therapy planning of patients with prostate cancer"</p> <p>BACKGROUND:</p> <p>In the era of image-guided radiotherapy, PET has become an important tool for tumor delineation in several types of cancer. The aim of this study was to evaluate the effect of this imaging modality in treatment planning of a cohort of patients with prostate cancer eligible for radiotherapy.</p> <p>METHODS:</p> <p>From September 2011 to January 2016, 135 consecutive patients (median age 69 years, range: 53-89) were referred to our department for radiation therapy with radical intent (n=28), for postoperative adjuvant (n=13) or salvage treatment (n=50), for re-irradiation (n=19), or for radiotherapy on oligometastases (n=25). Before planning the radiotherapy course, patients were submitted to carbon-11-choline PET (Cho-PET) to confirm the indication to radiotherapy and the irradiation volumes.</p> <p>RESULTS:</p> <p>Among the 135 patients subjected to Cho-PET, the indication to radiotherapy was modified in 66 (48.8%) cases based on the Cho-PET result. In particular, Cho-PET helped to better define the radiotherapy programme in 12 out of 28 (42.8%) patients who were candidates for primary radiation therapy, 33 (52.4%) of 63 patients undergoing adjuvant/salvage radiotherapy, and 21 out of 44 (47.7%) patients with relapsed/metastatic disease. Overall biochemical response is documented by mean and median prostate specific antigen values, which changed from 15.29 to 4.00 ng/ml, respectively, before to mean 4.74 ng/ml and median 0.81 ng/ml after therapy (P=0.05).</p> <p>CONCLUSION:</p> <p>In our series, Cho-PET had a significant effect on radiotherapy planning of patients affected by prostate cancer, determining a change in management in 48.8% of cases, considering all therapeutic indications</p>
Dataset related to article "Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer"
<p>This record contains raw data related to article “Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer"</p> <p>Abstract</p> <p>Tumor-associated macrophages (TAMs) are correlated with the progression of prostatic adenocarcinoma (PCa). The mechanistic basis of this correlation and therapeutic strategies to target TAMs in PCa remain poorly defined. Here, single-cell RNA sequencing was used to profile the transcriptional landscape of TAMs in human PCa, leading to identification of a subset of macrophages characterized by dysregulation in transcriptional pathways associated with lipid metabolism. This subset of TAMs correlates positively with PCa progression and shorter disease-free survival and is characterized by an accumulation of lipids that is dependent on Marco. Mechanistically, cancer cell-derived IL-1β enhances Marco expression on macrophages, and reciprocally, cancer cell migration is promoted by CCL6 released by lipid-loaded TAMs. Moreover, administration of a high-fat diet to tumor-bearing mice raises the abundance of lipid-loaded TAMs. Finally, targeting lipid accumulation by Marco blockade hinders tumor growth and invasiveness and improves the efficacy of chemotherapy in models of PCa, pointing to combinatorial strategies that may influence patient outcomes.</p>
Single cell RNA-sequencing of vehicle- and UK5099-treated mouse prostate organoids
GEO Series GSE206555. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing.
Regulatory cistrome landscape of Foxa1 and Foxa2 during prostate cancer progression [ChIP-seq]
GEO Series GSE191182. Mus musculus. 6 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Starving advanced prostate cancer cells by pharmacological gluose deprivation with a resveratrol trimer trans-Gnetin H
GEO Series GSE240104. Homo sapiens; Mus musculus. 24 samples. Type: Expression profiling by high throughput sequencing.
Tamoxifen-induced Ghr deletion in SV40 C3(1) T-antigen mouse prostates
GEO Series GSE197683. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.